You are here

ACV meeting statement, meeting 17, 2 December 2020

Advisory Committee on Vaccines

7 January 2021

Section A: Submissions for registration

No submission for registration was discussed.

The committee provided high-level comment on pending submissions for vaccines for SARS-CoV-2 disease that will use the provisional approval pathway. Areas covered included:

  • factors that should be considered when determining the benefit-risk balance for potential provisional registration of COVID-19 vaccines
  • the theoretical/ potential safety concerns with new vaccine technologies (e.g. mRNA and genetically modified vaccines), potential areas of focus for evaluation, and risk minimisation strategies
  • use of digital expiry dates for vaccines with limited shelf life stability data at the point of registration (if approved).

Section B: Safety

The committee provided advice on the duration of a pharmacovigilance study that is included in a Risk Management Plan.

Section C: Immunisation Programs

No matter related to immunisation programs was discussed.

Further information

For further information on the ACV, please visit Advisory Committee on Vaccines or contact the ACV by email